Laboratory Medicine 2.0 holds much promise, but we have many challenges to overcome before it is a reality.

Will we be able to move away from volume based testing to value based testing? Will we be able to show definitively that patient outcomes and overall levels of health can be improved using laboratory methods? And will we be able to move away from sick care and more towards a system of wellness care?

Variants of Uncertain Significance (VUS) cause tension but really shouldn't.

"Hang on! genetic variants are actually very, very common."

We saw tension between investor demands which is profitability and the interests of patients which is accuracy.

We can now test anyone for nearly any genetic mutation or alteration. What could possibly go wrong?

Julie Eggington, MS, PhD, co-founder and CEO of Center for Genomic Interpretation joins us this week.

What do we have to look forward to in the coming decade?

How can we spur innovation?

Who is the customer?

Hannah Mamuszka, CEO of Alva10 tells us how cost-based pricing and the commoditization of diagnostic tests has stifled innovation. The promise of value-based pricing, though, is still very much alive. The key, she says, lies in restructuring the relationship between the diagnostics providers and the payors.

"This is a golden age; we're just scratching the surface."